The European psychiatric association (EPA)–early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment

Schoretsanitis, Georgios (57038754800)Georgios (57038754800)SchoretsanitisCorrell, Christoph U. (57203102810)Christoph U. (57203102810)CorrellAgorastos, Agorastos (35483205500)Agorastos (35483205500)AgorastosCompaired Sanchez, Alejandro (59182984300)Alejandro (59182984300)Compaired SanchezErzin, Gamze (57189375175)Gamze (57189375175)ErzinGrigoras, Ruxandra M. (57206847199)Ruxandra M. (57206847199)GrigorasGrizelj Benussi, Mateja (58184516400)Mateja (58184516400)Grizelj BenussiGondek, Tomasz M. (57015264400)Tomasz M. (57015264400)GondekGuloksuz, Sinan (57215571180)Sinan (57215571180)GuloksuzHøjlund, Mikkel (57193721751)Mikkel (57193721751)HøjlundJerotic, Stefan (57207916809)Stefan (57207916809)JeroticKilic, Ozge (55895132900)Ozge (55895132900)KilicMetaj, Enita (57930776100)Enita (57930776100)MetajSidhu, Deshwinder Singh (57219768973)Deshwinder Singh (57219768973)SidhuSkandali, Nikolina (24473837400)Nikolina (24473837400)SkandaliSkuhareuski, Aliaksei (57211890428)Aliaksei (57211890428)SkuhareuskiTveito, Marit (59878849200)Marit (59878849200)TveitoWolthusen, Rick P. F. (58629445700)Rick P. F. (58629445700)WolthusenChumakov, Egor (57202854981)Egor (57202854981)Chumakovde Filippis, Renato (57203855513)Renato (57203855513)de Filippis2025-06-122025-06-122024https://doi.org/10.1080/15622975.2024.2367138https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196614874&doi=10.1080%2f15622975.2024.2367138&partnerID=40&md5=6190ce2185ca17a957cd024b42923ddchttps://remedy.med.bg.ac.rs/handle/123456789/1360Objectives: This survey assessed psychiatry residents’/early-career psychiatrists’ attitudes towards the utility of therapeutic drug monitoring (TDM) of antipsychotics. Methods: A previously developed questionnaire on attitudes on TDM utility during antipsychotic treatment was cross-sectionally disseminated by national coordinators between 01/01/2022–31/12/2023. The frequency of using TDM for antipsychotics other than clozapine was the main outcome in a linear regression analysis, including sex, clinical setting, caseload, and factors generated by an exploratory factor analysis. Comparisons between residents and early-career psychiatrists, respondents working in in- and outpatient settings, and low-/middle- and high–income countries were performed. Results: Altogether, 1,237 respondents completed the survey, with 37.9% having never used TDM for antipsychotics. Seven factors explained 41% of response variance; six of them were associated with frequency of TDM use (p < 0.05). Items with highest loadings for factors included clinical benefits of TDM (factors A and E: 0.7), negative expectations for beliefs of patients towards TDM (factor B: 0.6–0.7), weak TDM scientific evidence (factor C: 0.8), and TDM availability (factor D: −0.8). Respondents from low-/middle-income countries were less likely to frequently/almost always use TDM compared to high-income countries (9.4% vs. 21.5%, p < 0.001). Discussion: TDM use for antipsychotics was poor and associated with limited knowledge and insufficient availability. © 2024 Informa UK Limited, trading as Taylor & Francis Group.Early career psychiatrists (ECPs)personalised medicinepsychopharmacologyschizophreniatherapeutic drug monitoring (TDM)The European psychiatric association (EPA)–early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment